Bioventus Receives FDA Premarket Approval for DUROLANE

Bioventus received FDA premarket approval for DUROLANE single-injection hyaluronic acid (HA) to treat pain associated with knee osteoarthritis (OA). U.S. launch is slated for early 2018.

DUROLANE is indicated to treat knee OA pain in patients that have not adequately responded to conservative therapy or simply analgesics. The product has been...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us